Thermo Fisher issued guidance for 2026 revenue growth of 4–6% and reported Q4 2025 results that beat estimates, driven by life‑sciences solutions and bioprocess strength. The company posted full‑year revenue of $44.56 billion and highlighted double‑digit growth in life‑sciences solutions for the quarter. Management cited robust demand in bioprocess consumables and instrument placements, while specialty diagnostics and laboratory products supported margin resilience. Thermo Fisher reiterated investments in R&D and capacity to serve expanding biologics and cell‑and‑gene manufacturing markets. The outlook reflects healthier capex trends in pharma and biomanufacturing and suggests incremental recovery in instrument orders. For suppliers and CDMOs, Thermo Fisher’s guidance signals continued upstream demand for reagents, consumables, and single‑use systems. Market participants will track whether the firm sustains margin expansion while integrating ongoing investments for capacity, automation, and service networks tied to fast‑growing biologics demand.